Finance

Lists
Why is RNTX down ६.०३%?
Dive Deeper
RNTX:NASDAQ
Rein Therapeutics Inc
US$ ०.८०
-६.०३%
(-०.०५१) 1D
US$ ०.७९
-०.९७% (-०.००७८)
After hours
Closed: अक्टोबर २, १६:००:०० GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RNTX...
Open
US$ ०.८५
High
US$ ०.८६
Low
US$ ०.७८
Mkt. cap
६.९२ करोड
Avg. vol.
४.७२ लाख
Volume
४.८१ लाख
52-wk high
US$ २.१८
52-wk low
US$ ०.६९
EPS
-US$ १.५९
Beta
१.३६
Shares outstanding
८.६३ करोड
No. of employees
१०
Open
US$ ०.८५
High
US$ ०.८६
Low
US$ ०.७८
Mkt. cap
६.९२ करोड
Avg. vol.
४.७२ लाख
Volume
४.८१ लाख
52-wk high
US$ २.१८
52-wk low
US$ ०.६९
EPS
-US$ १.५९
Beta
१.३६
Shares outstanding
८.६३ करोड
No. of employees
१०
News stories
From web sources and news partners
Simply Wall Street
Simply Wall Street
·
२४ मिनेट पहिले
Long Lasting Symptom Relief Data Could Be A Game Changer For Vor Biopharma Stock
FXLeaders
FXLeaders
·
३६ मिनेट पहिले
Dow Jones and Nasdaq Futures Open Higher as Buyers Target New Records
Simply Wall Street
Simply Wall Street
·
१ घण्टा पहिले
Phase 2 Trial Plans Could Be A Game Changer For Absci Stock (ABSI)
USA Today
USA Today
·
१२ घण्टा पहिले
Is a stock market correction coming? Most Americans think so
About Rein Therapeutics Inc
CEO-
Employees१०
Founded२००१
Headquartersअस्टिन, टेक्सस, संयुक्त राज्य अमेरिका
Sector-
Websitereintx.com
Analyst ratings
Based on 2 analysts giving stock ratings to RNTX in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for RNTX in the last 3 months.
Highest
Current US$ ०.८०
US$ ८.०० (+८९९.१३%)
Average
US$ ६.०० (+६४९.३४%)
Lowest
US$ ४.०० (+३९९.५६%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brandon Folkes
H.C. Wainwright
Buy
Maintained
US$ ८.००
+८९९.१%
09/21/2026
Jason McCarthy
Maxim Group
Buy
Maintained
US$ ४.००
+३९९.६%
08/17/2026
Kemp Dolliver
Brookline Capital Markets
Hold
Downgraded
-
-
01/21/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
१६.८१ लाख
२०.०१ लाख
३०.७३ लाख
३६.३८ लाख
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
३८.११ लाख
१९.५८ लाख
२१.५७ लाख
२४.३८ लाख
Operating expense
५४.९२ लाख
३९.५९ लाख
५२.३० लाख
६०.७६ लाख
Total operating expenses
५४.९२ लाख
३९.५९ लाख
५२.३० लाख
६०.७६ लाख
Operating income
-५४.९२ लाख
-३९.५९ लाख
-५२.३० लाख
-६०.७६ लाख
Other non operating income
-८९.०० हजार
-२०.०० हजार
-६.०८ लाख
-२.९९ लाख
EBT including unusual items
-५५.८१ लाख
-३.२७ करोड
-५८.३८ लाख
-६३.७५ लाख
EBT excluding unusual items
-५५.८१ लाख
-३९.७९ लाख
-५८.३८ लाख
-६३.७५ लाख
Income tax expense
-
-७.१२ लाख
-
-
Effective tax rate
-
२.१८%
-
-
Other operating expenses
-
-
-
-
Net income
-५५.८१ लाख
-३.२० करोड
-५८.३८ लाख
-६३.७५ लाख
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-५४.९२ लाख
-३९.५९ लाख
-५२.३० लाख
-६०.७६ लाख
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google एपहरू